Ophthalmology Deals Are Up 1100% in 2026 — Here's the Data

Twelve ophthalmology deals closed between March and September 2026, compared to exactly one in the prior six-month window — an 1100% increase that marks the sharpest therapeutic-area acceleration we've tracked this year. The period from 2025-09-05 to 2026-03-05 was a desert; the period from 2026-03-05 to 2026-09-05 was a land grab. The catalyst is straightforward: Big Pharma's retinal and inflammation pipelines are thinning at the exact moment gene therapy and complement biology are producing clinical-stage assets worth buying.

The Data — Ophthalmology Deal Activity, Period over Period

This is not a noisy blip in a small dataset. The magnitude of the swing — from near-zero to double digits — reflects a genuine strategic reorientation by multiple large pharma companies simultaneously. When you see AbbVie, Biogen, Merck, and J&J all entering ophthalmology licensing 2026 transactions within a 90-day window, you're watching a consensus form in real time.

What's Driving the Trend

Pipeline gaps are the primary accelerant. Regeneron's EYLEA franchise, even with the biosimilar clock ticking, demonstrated that a dominant retinal asset can generate $6B+ annually. Every top-20 pharma company without a credible retinal pipeline is now exposed. Biogen's pivot toward ophthalmology after its neurodegeneration setbacks is the clearest example: the company needs a durable revenue engine, and complement-mediated retinal diseases offer exactly that. Apellis's SYFOVRE, despite a rocky commercial launch, validated the geographic atrophy market as real. At $5.6B total deal value, Biogen is paying for the platform, not just the molecule.

Gene therapy is finally crossing the credibility threshold in the eye. The REGENXBIO–AbbVie and MeiraGTx–J&J deals both center on AAV-delivered gene therapies for retinal conditions. The eye remains the most favorable compartment for gene therapy: small volume, immune-privileged, surgically accessible, and amenable to one-time dosing narratives that payers will fund. AbbVie's interest in REGENXBIO's RGX-314 (anti-VEGF gene therapy for wet AMD) reflects a bet that the next generation of retinal treatment won't be monthly injections — it will be one-and-done gene delivery. J&J's $130M upfront to MeiraGTx for inherited retinal disease assets confirms the thesis across a second modality and indication.

Competitive urgency is compressing timelines. The ophthalmology deal trends 2026 data shows that once Biogen made its move in late June, it likely accelerated AbbVie's and Merck's decisions. When one major acquirer pays a premium, it resets expectations for every remaining target. Biotech boards that were considering IPOs or independent commercialization paths suddenly face a credible alternative: take the upfront, de-risk, and let the pharma partner handle the $300M–$500M commercial buildout required for retinal launches. The EyeBio–Merck transaction in April and AbbVie's deal with Aldeyra Therapeutics in the same week suggest parallel diligence processes that converged almost simultaneously.

Notable Deals

The Apellis–Biogen deal is the headline, and it deserves scrutiny. At $5.6B with upfront equal to total deal value, this is a full acquisition, not a milestone-laden option play. Biogen paid a significant premium over Apellis's pre-deal market cap, signaling desperation as much as conviction. SYFOVRE's geographic atrophy label, combined with Apellis's broader complement platform, gives Biogen an immediate revenue-generating asset and a pipeline — but the commercial execution risk in GA remains real. Penetration has been slower than bulls projected, and Biogen's ophthalmology commercial infrastructure is nonexistent. They're buying a company and building a salesforce simultaneously. Whether this deal looks brilliant or bloated in 18 months depends entirely on GA market expansion.

The gene therapy cluster — REGENXBIO–AbbVie and MeiraGTx–J&J — tells a different story. These are earlier-stage bets with more structured economics. J&J's $130M upfront to MeiraGTx for inherited retinal disease programs is well within the range you'd expect for Phase I/II gene therapy assets, based on Deal Benchmarks for the modality. AbbVie's REGENXBIO deal, while financial terms weren't disclosed, likely includes significant milestone-driven components — a structure that makes sense given RGX-314's clinical risk in a crowded anti-VEGF landscape.

The Merck–EyeBio and AbbVie–Aldeyra transactions round out the picture. Merck's interest in EyeBio likely centers on novel biologic approaches to retinal disease, while AbbVie's Aldeyra deal (with AbbVie as licensee) signals the company's interest in ocular inflammation beyond its Allergan legacy. AbbVie appearing on both sides of the table — as buyer of REGENXBIO and Aldeyra assets — underscores its intent to build a next-generation ophthalmology portfolio from scratch, not simply maintain the dry eye and glaucoma franchises it inherited.

What This Means for BD Teams Right Now

If you're a biotech with clinical-stage ophthalmology assets, this is a seller's market — full stop. The data is unambiguous: five major pharma companies entered the market in under six months. That level of demand compression hasn't occurred in ophthalmology since the anti-VEGF era. You have leverage. Use it to negotiate higher upfronts relative to total deal value, shorter milestone timelines, and co-promotion rights if you have any commercial ambition. The Apellis deal — 100% upfront as a share of TDV — is an extreme data point, but it shifts the anchor for every subsequent negotiation.

For preclinical assets, the window is open but narrowing. Gene therapy platforms with retinal applications are the most sought-after, but complement targets, novel anti-VEGF mechanisms, and ocular inflammation are all in play. If you're sitting on a differentiated mechanism with IND-enabling data, run a competitive process now. Don't wait for Phase I data to start conversations — pharma BD teams are already reaching out to preclinical-stage companies, and several of the undisclosed deals in our dataset reflect exactly this dynamic.

If you're a pharma BD team, speed matters more than perfection. The best retinal assets are being taken off the table monthly. Waiting for Phase II readouts to de-risk means paying 2–3x what you'd pay today, or losing the asset entirely to a competitor with higher risk tolerance. Structure deals with option-based frameworks: pay a meaningful upfront ($50M–$150M for preclinical-to-Phase I gene therapy), retain opt-in rights at a clinical milestone, and cap your total exposure with carefully defined development milestones. Use Solidus to model these structures against the current ophthalmology deal trends 2026 data and ensure your term sheets are competitive.

Deal structures are shifting toward higher upfront percentages. Across the five notable deals, the disclosed transactions show upfronts representing 100% of TDV (Apellis–Biogen, MeiraGTx–J&J). This is atypical for the broader market, where upfronts have historically averaged 20–30% of total deal value for licensing transactions. It reflects the competitive intensity of this specific window. BD teams should prepare their boards for higher upfront cash commitments; committees that still benchmark against 2024 ophthalmology norms will lose every competitive process in 2026.

Benchmark your deal against current market rates. Whether you're structuring an ophthalmology licensing 2026 transaction or evaluating an inbound term sheet, the data has shifted dramatically in six months. Use the Ambrosia calculator to pressure-test your economics against the latest comparable transactions and ensure you're negotiating from the right baseline.